Navigation Links
Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
Date:9/25/2007

rations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.

Contact:

Amy P. Sharpless

(609) 452-3643<
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007
3. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
4. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
5. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...c. 1 TargeGen has announced that a...a multi-center, US-based clinical,trial of TG1013... scheduled at,the 2008 American Society of Hemato...entation are as follows:, Title: ...ble, JAK2-Selective Inhibi...
(Date:12/1/2008)...nce is still the best policy , , ROCHESTER...tudy from Mayo Clinic finds the use of the drug th... hepatitis, an acute inflammation of the liver cau...ts of the study are published in the December issu....org/ ). , , VIDEO ALERT: Additional audio...
(Date:12/1/2008)...c. 1 Vical Incorporated ... $1.0 million milestone payment from Merck & C...Phase I clinical trial of an investigational plasm...e is based on Vical,s DNA gene delivery technology...e (hTERT). hTERT is the subject of separate licens...
(Date:11/27/2008)...ds the majority of acute lymphoblastic leukemia re...he time of diagnosis , , MEMPHIS, Tenn., No... Jude Children,s Research Hospital have identified...f children with acute lymphoblastic leukemia (ALL)...to designing treatments for ALL relapse in childre...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3High pollution linked to poor lung function growth in children in Mexico City 50 1High pollution linked to poor lung function growth in children in Mexico City 50 2Clinical depression linked to abnormal emotional brain circuits 46 1Clinical depression linked to abnormal emotional brain circuits 46 2Clinical depression linked to abnormal emotional brain circuits 46 3HPV vaccine does not appear to be effective for treating pre existing HPV infection 42 1HPV vaccine does not appear to be effective for treating pre existing HPV infection 42 2HPV vaccine does not appear to be effective for treating pre existing HPV infection 42 3New review suggests caution on drugs to raise good cholesterol 38 1New review suggests caution on drugs to raise good cholesterol 38 2New review suggests caution on drugs to raise good cholesterol 38 3
...ESTERSHIRE , England, 21 June 2007, Malvern Instru... users of the company,s,near infrared chemical ima...ok place on 13 June 2007 was hosted by AstraZeneca...of the world,s major,pharmaceutical companies join...program that included oral and poster presentation...
...INGTON, June 20, 2007 /PRNewswire-USNewswire/ -- T...nt Bush on stem cell,veto and executive order: , E... I,m glad you,re here. America is a,nation that le...ative spirit is making possible incredible advance...ses. America is also a,nation founded on the princ...
Other Medicine Technology:Malvern initiates European user group meetings for chemical imaging 2Malvern initiates European user group meetings for chemical imaging 3Remarks by President Bush on Stem Cell Veto and Executive Order 2Remarks by President Bush on Stem Cell Veto and Executive Order 3Remarks by President Bush on Stem Cell Veto and Executive Order 4Remarks by President Bush on Stem Cell Veto and Executive Order 5Remarks by President Bush on Stem Cell Veto and Executive Order 6
(Date:12/1/2008)...t the availability of a portable eight-slice compu...an significantly increase the number of stroke vic...nt. Results of the study, conducted at North Shore...ss., will be presented today at the annual meeting...A). , "The hospital,s acquisition of a portable...
(Date:12/1/2008)...es with President on U.S. HIV/AIDS Initiatives and...ack Civil Forum on Global Health , , WASHIN...ush was honored on the 20th anniversary of World A...ACE" given by Dr. Rick Warren on behalf of the Glo...rum on Global Health. The award, given in recogni...
(Date:12/1/2008)...e/ -- In the face of one of the most,severe econo...Health Board of,Directors has approved an investm... the Sutter Health Retirement Plan. Employee pensi...cks and bonds, have been among the biggest,casual...onservatively,invested, the Sutter Health Retirem...
(Date:12/1/2008)...all/ -- ViroPharma Incorporated,(Nasdaq: VPHM )...lemental,Biologics License Application (sBLA) to ...inryze(TM) C1 Inhibitor (human) as a treatment for... The sBLA is based on a re-analysis and resu...atment study of Cinryze and interim data from an o...
Breaking Medicine News(10 mins):Health News:Portable CT increases chance of stroke survival and recovery 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 3Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 4Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 5Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5
... the death of 200 cattle due to anthrax in the las...pread the deadly disease to the cattle in the prov...ting due to severe shortage of vaccines. Infact, t...g vaccines, should be the number one priority in t...
...issue of Canadian Journal Emergency Medicine, sug...ted to over 3% (40,000) of 1.2 million emergency v.... // The study Researchers at the Toronto-based I...es (ICES) looked at the gunshots and knife wounds ...
...clinics in China have been asked to be watchful ab...le cases. //The Ministry of Health has also reques... in diarrhea cases. As Norovirus infections are h...ercise caution while eating in restaurants and hot...
... head and neck tumor cells that indicates which ce...e finding is the first evidence of cancer stem cel...e the small number of cancer cells that replicate ...ieve current cancer treatments sometimes fail beca...
Other Medicine News:Health News:Stem Cell Marker Identified in Head and Neck Cancer 2
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies.
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels.
The new Multichamber one-piece baseplate is designed specifically for Urostomates; it is significantly thicker than the current Assura, allowing it to resist urine erosion for longer. The product is
...t for the screening of factor-V-related APC resist...test for the factor V:Q506 mutation is obtained by...-DEF Plasma bioreagent. The test design makes it p...omozygous factor V genotypes. It also allows for a...
Medicine Products: